Legal & General Group
GYRE icon

Legal & General Group’s Gyre Therapeutics GYRE Stock Holding History

Legal & General Group’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.71K Sell
1,251
-154
-11% -$1.2K ﹤0.01% 3214
2025
Q4 		$9.89K Buy
1,405
+545
+63% +$4.21K ﹤0.01% 3249
2025
Q3 		$6.44K Sell
860
-653
-43% -$4.96K ﹤0.01% 3349
2025
Q2 		$11.1K Buy
1,513
+910
+151% +$7.94K ﹤0.01% 3254
2025
Q1 		$4.64K Hold
603
– – ﹤0.01% 3286
2024
Q4 		$7.29K Hold
603
– – ﹤0.01% 3302
2024
Q3 		$7.62K Hold
603
– – ﹤0.01% 3319
2024
Q2 		$7.13K Buy
+603
New +$8.28K ﹤0.01% 3351
2021
Q2 		– Sell
-362
Closed -$14K – 3567
2021
Q1 		$14K Buy
362
+89
+33% +$4.07K ﹤0.01% 3277
2020
Q4 		$13K Hold
273
– – ﹤0.01% 3244
2020
Q3 		$9K Sell
273
-18
-6% -$704 ﹤0.01% 3265
2020
Q2 		$13K Buy
+291
New +$13.7K ﹤0.01% 3237
2019
Q3 		– Sell
-236
Closed -$13K – 3381
2019
Q2 		$13K Hold
236
– – ﹤0.01% 3311
2019
Q1 		$14K Hold
236
– – ﹤0.01% 3190
2018
Q4 		$14K Hold
236
– – ﹤0.01% 3202
2018
Q3 		$19K Hold
236
– – ﹤0.01% 3218
2018
Q2 		$21K Buy
+236
New +$41.4K ﹤0.01% 3174

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Legal & General Group's GYRE Position: Q1 2026 in Review

Legal & General Group reduced its Gyre Therapeutics (GYRE) stake by 11% in Q1 2026, selling an estimated $1.2K and leaving 1,251 shares worth $8.71K. The position accounts for ﹤0.01% of the portfolio, ranked #3214.

Legal & General Group first reported a position in GYRE in Q2 2018 and has held it in 17 quarters since. The position peaked at $21K in Q2 2018. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • Legal & General Group held 1,251 shares of Gyre Therapeutics worth $8.71K as of Q1 2026.
  • Legal & General Group sold 154 Gyre Therapeutics shares in Q1 2026, an estimated $1.2K.
  • Gyre Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3214 holding.
  • Legal & General Group first reported a position in Gyre Therapeutics in Q2 2018 and has held it in 17 quarters since.
  • Legal & General Group's Gyre Therapeutics position peaked at $21K in Q2 2018.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.